Compass Therapeutics/$CMPX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Ticker
$CMPX
Sector
Primary listing
Employees
39
Headquarters
Website
CMPX Metrics
BasicAdvanced
$409m
-
-$0.40
0.67
-
Price and volume
Market cap
$409m
Beta
0.67
52-week high
$6.88
52-week low
$1.61
Average daily volume
4.1m
Financial strength
Current ratio
19.038
Quick ratio
18.94
Long term debt to equity
4.514
Total debt to equity
5.251
Profitability
EBITDA (TTM)
-75.021
Management effectiveness
Return on assets (TTM)
-27.91%
Return on equity (TTM)
-45.95%
Valuation
Price to book
2.19
Price to tangible book (TTM)
2.19
Price to free cash flow (TTM)
-7.23
Free cash flow yield (TTM)
-13.83%
Free cash flow per share (TTM)
-0.314
Growth
Earnings per share change (TTM)
0.22%
3-year earnings per share growth (CAGR)
3.94%
What the Analysts think about CMPX
Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.
CMPX Financial Performance
Revenues and expenses
CMPX Earnings Performance
Company profitability
CMPX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs